线粒体靶向铱(Ⅲ)配合物克服肿瘤耐药

doi:10.3866/PKU.DXHX202110094

Abstract

Abstract:

Despite the great success of platinum-based drugs in clinical cancer treatments, the side effects and drug resistance greatly limit their clinical application and curative effect. Possessing the stable structure and unique three-dimensional configuration, iridium (Ⅲ) complexes can effectively jump out of the limitations of traditional platinum-based drugs. On the other hand, mitochondrial science is one of the most active interdiscipline. As a predictable therapeutic target, mitochondrial-targeting antitumor agents have prominent advantages in overcoming tumour drug resistance. Herein, we introduce the mechanism of platinum chemotherapeutic drug resistance. Based on the recent research of our group, we also briefly summarize the research progress of mitochondrial-targeting iridium(Ⅲ) complexes to overcome the tumor drug resistance.

Key words: Cyclometalated iridium(Ⅲ) complexes, Mitochondrial targeting, Cisplatin, Tumour drug-resistant

Kai Xiong, Yu Chen, Liangnian Ji, Hui Chao. Overcome Tumour Drug Resistance with Mitochondrial-Targeting Cyclometalated Iridium(Ⅲ) Complexes[J].University Chemistry, 2022, 37(3): 2110094.

Figures/Tables 7

References 26

1	Bray F. ; Ferlay J. ; Soerjomataram I. ; Siegel R. L. ; Torre L. A. ; Jemal A. CA Cancer J. Clin. 2018, 68 (6), 394. doi: 10.3322/caac.21492
2	Sung H. ; Ferlay J. ; Siegel R. L. ; Laversanne M. ; Soerjomataram I. ; Jemal A. ; Bray F. CA Cancer J. Clin. 2021, 71 (3), 209. doi: 10.3322/caac.21660
3	吴大维; 黄慧瑶; 唐玉; 王海学; 王骏; 王书航; 房虹; 杨雪源; 李静; 王欣; 等. 中华肿瘤杂志, 2021, 43 (2), 218. doi: 10.3760/cma.j.cn112152-20201221-01089
4	Rosenberg B. ; Vancamp L. ; Trosko J. E. ; Mansour V. H. Nature 1969, 222 (5191), 385. doi: 10.1038/222385a0
5	Jung Y. ; Lippard S. J. Chem. Rev. 2007, 107 (5), 1387. doi: 10.1021/cr068207j
6	Vasan N. ; Baselga J. ; Hyman D. M. Nature 2019, 575 (7782), 299. doi: 10.1038/s41586-019-1730-1
7	Hanahan D. ; Weinberg R. A. Cell 2011, 144 (5), 646. doi: 10.1016/j.cell.2011.02.013
8	Koppenol W. H. ; Bounds P. L. ; Dang C. V. Nat. Rev. Cancer 2011, 11 (5), 325. doi: 10.1038/nrc3038
9	Yang Y. ; Karakhanova S. ; Hartwig W. ; D'Haese J. G. ; Philippov P. P. ; Werner J. ; Bazhin A. V. J. Cell. Physiol. 2016, 231 (12), 2570. doi: 10.1002/jcp.25349
10	Wu W.-S. Cancer Metastasis Rev. 2006, 25 (4), 695.
11	White J. D. ; Haley M. M. ; DeRose V. J. Acc. Chem. Res. 2015, 49 (1), 56.
12	Borst P. ; Evers R. ; Kool M. ; Wijnholds J. J. Natl. Cancer Inst. 2000, 92 (16), 1295. doi: 10.1093/jnci/92.16.1295
13	Galluzzi L. ; Senovilla L. ; Vitale I. ; Michels J. ; Martins I. ; Kepp O. ; Castedo M. ; Kroemer G. Oncogene 2012, 31 (15), 1869. doi: 10.1038/onc.2011.384
14	Ferry K. V. ; Hamilton T. C. ; Johnson S. W. Biochem. Pharmacol. 2000, 60 (9), 1305. doi: 10.1016/S0006-2952(00)00441-X
15	Assaraf Y. G. ; Brozovic A. ; Goncalves A. C. ; Jurkovicova D. ; Line A. ; Machuqueiro M. ; Saponara S. ; Sarmento-Ribeiro A. B. ; Xavier C. P. R. ; Vasconcelos M. H. Drug Resist. Updat. 2019, 46, 100645. doi: 10.1016/j.drup.2019.100645
16	Chen Y. ; Guan R. ; Zhang C. ; Huang J. ; Ji L. ; Chao H. Coord. Chem. Rev. 2016, 310, 16. doi: 10.1016/j.ccr.2015.09.010
17	Chen Y. ; Rees T. W. ; Ji L. ; Chao H. Curr. Opin. Chem. Biol. 2018, 43, 51. doi: 10.1016/j.cbpa.2017.11.006
18	Ouyang C. ; Chen L. ; Rees T. W. ; Chen Y. ; Liu J. ; Ji L. ; Long J. ; Chao H. Chem. Commun. 2018, 54 (49), 6268. doi: 10.1039/C8CC02795A
19	Zhang C. ; Guan R. ; Liao X. ; Ouyang C. ; Rees T. W. ; Liu J. ; Chen Y. ; Ji L. ; Chao H. Chem. Commun. 2019, 55 (83), 12547. doi: 10.1039/C9CC05998A
20	Xiong K. ; Qian C. ; Yuan Y. ; Wei L. ; Liao X. ; He L. ; Rees T. W. ; Chen Y. ; Wan J. ; Ji L. ; Chao H. Angew. Chem. Int. Ed. 2020, 59 (38), 16631. doi: 10.1002/anie.202006089
21	He L. ; Xiong K. ; Wang L. ; Guan R. ; Chen Y. ; Ji L. ; Chao H. Chem. Commun. 2021, 57 (67), 8308. doi: 10.1039/D1CC02178H
22	Guan R. ; Chen Y. ; Zeng L. ; Rees T. W. ; Jin C. ; Huang J. ; Chen Z. S. ; Ji L. ; Chao H. Chem. Sci. 2018, 9 (23), 5183. doi: 10.1039/C8SC01142G
23	Guan R. L. ; Xie L. N. ; Wang L. L. ; Zhou Y. ; Chen Y. ; Ji L. N. ; Chao H. Inorg. Chem. Front. 2021, 8 (7), 1788. doi: 10.1039/D0QI01430C
24	Xiong, K.; Zhou, Y.; Lin, X.; Kou, J.; Lin, M.; Guan, R.; Chen, Y.; Ji, L.; Chao, H. Photochem. Photobiol. 2021, in press. doi: 10.1111/php.13404
25	Li J. ; Chen H. ; Zeng L. ; Rees T. W. ; Xiong K. ; Chen Y. ; Ji L. ; Chao H. Inorg. Chem. Front. 2019, 6 (4), 1003. doi: 10.1039/C9QI00081J
26	Ke L. ; Zhang C. ; Liao X. ; Qiu K. ; Rees T. W. ; Chen Y. ; Zhao Z. ; Ji L. ; Chao H. Chem. Commun. 2019, 55 (69), 10273. doi: 10.1039/C9CC05610F

铱配合物	λ_em/nm	A549R细胞IC₅₀/(μmol∙L⁻¹)	克服顺铂耐药能力^a	优点及待改进之处
Ir-Pt	–	2.46 ± 0.28	32.03	优点：成功实现调控顺铂衍生物作用靶点，诱导顺铂耐药细胞坏死，协同克服肿瘤耐药待改进之处：顺铂衍生物水解不可控，可能引发副作用
Ir-Ru	–	0.45 ± 0.1	205.56	优点：光活化具有时空选择性；PACT和PDT双模式协同高效克服肿瘤耐药待改进之处：光致激活后PACT和PDT部分无发射光，无法实时原位示踪
Ir1	–	2.50 ± 0.23	30.24	优点：首例金属基线粒体拓扑酶抑制剂克服肿瘤耐药待改进之处：配合物无发光，无法实时原位示踪
Ir2	–	2.68 ± 0.27	28.21	优点：首例金属基线粒体拓扑酶抑制剂克服肿瘤耐药待改进之处：配合物无发光，无法实时原位示踪
Ir3	671	0.48 ± 0.02	203.73	优点：红色发光，可实现实时原位示踪；具有广谱抗肿瘤活性；细胞选择性高；诱导细胞胀亡克服肿瘤耐药待改进之处：诱导胀亡机制尚不明确
Ir4	605	0.75 ± 0.05	130.39
Ir5	657	0.64 ± 0.05	152.80
Ir6	641	0.82 ± 0.07	119.26
Ir7	639	3.21 ± 0.06	30.46	优点：多途径抗肿瘤能力克服耐药待改进之处：作用机制有待研究
Ir8	635	1.20 ± 0.03	81.49	优点：多途径抗肿瘤能力克服耐药待改进之处：作用机制有待研究

Overcome Tumour Drug Resistance with Mitochondrial-Targeting Cyclometalated Iridium(Ⅲ) Complexes

RichHTML

PDF

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 26

Related Articles 1

Metrics

Recommended 0